Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.
Name:
PIIS2352512617302370.pdf
Size:
417.6Kb
Format:
PDF
Description:
Full text, Open Access article
Affiliation
Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, United KingdomIssue Date
2018-04
Metadata
Show full item recordCitation
Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. 2018, 4(3): 229-231 JAAD Case RepJournal
JAAD Case ReportsDOI
10.1016/j.jdcr.2017.09.028PubMed ID
29687056Type
ArticleLanguage
enDescription
Lymphoma Research TeamISSN
2352-5126ae974a485f413a2113503eed53cd6c53
10.1016/j.jdcr.2017.09.028
Scopus Count
Collections
Related articles
- Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
- Authors: Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L
- Issue date: 2017 Apr
- Immune-Mediated Toxic Epidermal Necrolysis.
- Authors: Keerty D, Koverzhenko V, Belinc D, LaPorta K, Haynes E
- Issue date: 2020 Aug 6
- Nivolumab-Induced Toxic Epidermal Necrolysis: Rare but Fatal Complication of Immune Checkpoint Inhibitor Therapy.
- Authors: Kim MC, Khan HN
- Issue date: 2021 May 13
- Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
- Authors: Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X
- Issue date: 2019 Jun 10
- Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
- Authors: Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R
- Issue date: 2019 Mar